Galectin-1 and -3 as biomarkers for capsular contracture. A pilot study

Completed

• Conditions: 10006295; capsular contracture

• Registration Number: NL-OMON44974
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- females aged 18 or over
- females who have developed capsular contracture (Baker score 1&2 and 3&4) after bilateral cosmetic breast augmentation with silicone breast implants at least one year after implant implantation
- females who who are on the waiting list for a breast augmentation will serve as a control group

Exclusion Criteria

- females who have a co-morbidity (e.g. diseases of the liver, lung, heart, kidney, or skin);
- females who have (a history of) cancer
- females who have a capsular contracture for more than 5 years
- females who have had silicone injections
- females who are currently smoking or smoked in the past year

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Serum and local Galectin-1, -3, HLA and IgE</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable. </p><br>